We constructed a prognostic model for HBV-HCC that includes five genes: DLAT, STC2, POF1B, S100A9, and CPS1. We analyzed the tumor microenvironment of different risk groups and assessed the efficacy of immunotherapy and drug treatment based on risk scores. Here, DLAT is linked to neoplasm.